TCB008

DRUG3 trials

Sponsors

TC Biopharm

Conditions

Acute Myeloid LeukemiaCOVID - 19Myelodysplastic Syndromes

Phase 1

ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML

Not yet recruitingNCT06463327

TC BiopharmAcute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2025-01-31End: 2027-06-30Target: 69Updated: 2024-06-17

Phase 2

A Phase II Safety and Tolerability Study of TCB008 in Patients With COVID-19

WithdrawnNCT04834128

TC BiopharmCOVID - 19

Start: 2021-12-13End: 2022-04-13Updated: 2023-04-21

ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)

TerminatedNCT05358808

TC BiopharmAcute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2022-08-15End: 2025-07-30Updated: 2025-09-30